ClinVar Miner

Submissions for variant NM_006206.6(PDGFRA):c.1214A>G (p.Tyr405Cys)

dbSNP: rs1553903757
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000633822 SCV000755095 uncertain significance Gastrointestinal stromal tumor 2023-06-04 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function. ClinVar contains an entry for this variant (Variation ID: 528600). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 405 of the PDGFRA protein (p.Tyr405Cys).
Ambry Genetics RCV002358777 SCV002656227 uncertain significance Hereditary cancer-predisposing syndrome 2023-09-14 criteria provided, single submitter clinical testing The p.Y405C variant (also known as c.1214A>G), located in coding exon 7 of the PDGFRA gene, results from an A to G substitution at nucleotide position 1214. The tyrosine at codon 405 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Baylor Genetics RCV004568388 SCV005055155 uncertain significance Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal 2024-02-13 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV005034209 SCV005665333 uncertain significance Idiopathic hypereosinophilic syndrome; Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal 2024-03-21 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.